Table 4.
Demographic, clinic and lab variables—asthmatics top vs. bottom levels of FEV1.
| Variable | Top (n: 10) | Bottom (n: 10) | p |
|---|---|---|---|
| FEV1 (% predicted) | 98.6 ± 2.54 | 45.20 ± 14.11 | <0.0001 |
| M/F, n (%) | 3/7 (30/70) | 5/5 (50/50) | 0.4 |
| Age (years), mean ± SD | 61.1 ± 17.20 | 58.5 ± 12.16 | 0.7 |
| Hypertension, n (%) | 4 (40) | 10 (100) | <0.0001 |
| Uncontrolled hypertension, n (%) | 1 (25) | 5 (50) | 0.06 |
| Family history for hypertension, n (%) | 7 (70) | 6 (60) | 0.64 |
| Diabetes, n (%) | 2 (20) | 2 (20) | 1 |
| Fasting glucose (mg/dL), mean ± SD | 103.75 ± 27.55 | 104.71 ± 32.87 | 0.9 |
| Past cerebral vascular event, n (%) | - | - | - |
| Past cardiac vascular event, n (%) | - | - | - |
| Past peripheral arterial disease, n (%) | - | - | - |
| Creatinine (mg/dL), mean ± SD | 0.81 ± 0.06 | 0.92 ± 0.25 | 0.2 |
| Creatinine Clearance (mL/min), mean ± SD | 91.95 ± 25.39 | 52 ± 41.61 | 0.02 |
| Statin use, n (%) | 2 (20%) | - | 0.15 |
| BMI (Kg/m2), mean ± SD | 28.00 ± 4.31 | 28.69 ± 4.94 | 0.7 |
| Total cholesterol (mg/dL), mean ± SD | 202.2 ± 36.92 | 207.83 ± 37.30 | 0.7 |
| HDL cholesterol (mg/dL), mean ± SD | 53.58 ± 18.8 | 64.5 ± 4.95 | 0.1 |
| Triglycerides (mg/dL), mean ± SD | 111.4 ± 46 | 74.66 ± 10 | 0.02 |
| Current smokers, n (%) | - | - | - |
| Past smokers, n (%) | 1 (10) | 5 (50) | 0.06 |
| WBC (mm3) | 7295 ± 2909 | 8555 ± 2297 | 0.3 |
| Severe asthma, n (%) | 4 (40) | 9 (90) | 0.02 |
| Asthma duration (years) | 14.7 ± 8.73 | 30.1 ± 20.03 | 0.04 |
| Oral steroid therapy, n (%) | 1 (10) | 2 (20) | 0.5 |
| ICS low dose, n (%) | 1 (10) | - | 0.3 |
| ICS medium dose, n (%) | - | - | - |
| ICS/LABA low dose ICS (n/%) | 2 (20) | - | 0.14 |
| ICS/LABA medium dose ICS (n/%) | 4 (40) | 3 (30) | 0.6 |
| ICS/LABA high dose ICS (n/%) | 3 (30) | 4 (40) | 0.6 |
| Mean ICS daily dose (mcg) | 400.4 ± 331.5 | 526.4 ± 487.8 | 0.5 |
| LAMA (n/%) | 3 (30) | 7 (70) | 0.08 |
| SABA (n/%) | 4 (40) | 7 (70) | 0.2 |
| LTRA (n/%) | 2 (20) | 5 (50) | 0.4 |
| Doxofylline (n/%) | - | 1 (10) | 0.3 |
| Biologic therapy (n/%) | - | 4 (40) | 0.03 |
| STEP GINA 2019 (n/%) 1,2 3,4 5 |
1 (10) 6 (60) 3 (30) |
- 3 (30) 7 (70) |
0.3 0.2 0.2 |
Data are presented as mean value ± SD; FEV1: forced expiratory volume in the 1st second; BMI: body mass index; WBC: white blood cells; ICS: inhaled corticosteroid; LABA: long-acting beta agonist; LAMA: long-acting muscarinic antagonist; SABA: short-acting beta agonist; LTRA: leukotriene receptor antagonist; FEV1: forced expiratory volume in the 1st second. Creatinine clearance has been calculated through Cockroft and Gault formulae.